TY - JOUR AU - Chang, Xiao AU - Deng, Lei AU - Ni, Wenjie AU - Li, Chen AU - Han, Weiming AU - Gao, Lin-rui AU - Wang, Shijia AU - Zhou, Zongmei AU - Chen, Dongfu AU - Feng, Qinfu AU - Liang, Jun AU - Bi, Nan AU - Lv, Jima AU - Gao, Shugeng AU - Mao, Yousheng AU - Xue, Qi AU - Xiao, Zefen PY - 2020 DA - 2020/09/14 TI - Salvage chemoradiation therapy for recurrence after radical surgery or palliative surgery in esophageal cancer patients: a prospective, multicenter clinical trial protocol JO - BMC Cancer SP - 877 VL - 20 IS - 1 AB - Currently, adjuvant therapy is not recommended for patients with thoracic esophageal squamous cell cancer (TESCC) after radical surgery, and a proportion of these patients go on to develop locoregional recurrence (LRR) within 2 years. Besides, there is no evidence for salvage chemoradiation therapy (CRT) in patients with residual tumor after esophagectomy (R1/R2 resection). In addition, factors like different failure patterns and relationship with normal organs influence the decision for salvage strategy. Here, we aimed to design a modularized salvage CRT strategy for patients without a chance of salvage surgery according to different failure patterns (including R1/R2 resection), and further evaluated its efficacy and safety. SN - 1471-2407 UR - https://doi.org/10.1186/s12885-020-07315-0 DO - 10.1186/s12885-020-07315-0 ID - Chang2020 ER -